ArticleAMB Express2025
Genome-wide analysis of Burkholderia for the management of antimicrobial-resistant in cystic fibrosis patients.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and prognostic impact of Burkholderia cepacia complex colonization and infection in patients with hematologic malignancies.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia is a significant pathogen that causes disease burden across the globe. In particular, Burkholderia cenocepacia and Burkholderia multivorans are the predominant isolates that infect people with cystic fibrosis (CF) and cause hospital-acquired infections. Understanding antimicrobial resistance and virulent factors among these species is of great significance for addressing this growing resistance burden. Initially, we retrieved 75 complete genome sequences of B. cenocepacia and B. multivorans from NCBI database and analysed them for antimicrobial resistance (AMR) and virulent factors. This yielded 368 antimicrobial resistance genes and 202 virulent factors after removing the duplicates. Further, a comprehensive interaction network was constructed using STRING, which was visualized and analysed using Cytoscape. Through cytoHubba and MCODE analysis, eight key hub genes FliF, FliG, FliM, FliS, FlgB, FlgC, FlgD and FlgK were identified. Additionally, a non-homology analysis was conducted to ensure that the key nodes do not exhibit similarity with the human genome and gut microbiota. Functional enrichment analysis revealed their significant role in the flagellar assembly pathway, particularly in bacterial motility, colonization and biofilm formation. Notably, seven hub genes were enriched in bacterial-type flagellum-dependent cell motility pathway and cellular localization. It is worth noting that 17,967 phytochemicals were exploited to identify the potent hit compounds against each of the identified hub genes. Interestingly, the hit molecules were found to form several key interactions with the targets, indicating their potential as promising therapeutic agents for combating AMR. Overall, the identified hub genes and their potent inhibitors present compelling targets for novel antimicrobial therapies in CF, underscoring the need for future experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.